Allogene Therapeutics Inc
(ALLO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -152,076 | -110,676 | -59,733 | -257,590 | -197,651 |
| Depreciation Amortization | 5,902 | 3,728 | 1,793 | 5,291 | 3,709 |
| Accounts payable and accrued liabilities | -1,830 | -758 | -336 | -503 | -537 |
| Other Working Capital | -10,675 | -10,530 | -8,294 | -24,799 | -30,069 |
| Other Operating Activity | 37,032 | 26,277 | 13,641 | 77,301 | 60,946 |
| Operating Cash Flow | $-121,647 | $-91,959 | $-52,929 | $-200,300 | $-163,602 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -386 | -143 | -99 | -694 | -437 |
| Purchase Of Investment | -109,880 | -60,146 | -50,225 | -361,475 | -314,501 |
| Sale Of Investment | 172,212 | 110,300 | 56,500 | 437,857 | 335,692 |
| Investing Cash Flow | $61,946 | $50,011 | $6,176 | $75,688 | $20,754 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 15,390 | 12,154 | 10,640 | 114,395 | 108,652 |
| Other Financing Activity | 6,908 | 6,908 | 3,350 | 2,280 | 2,280 |
| Financing Cash Flow | $22,298 | $19,062 | $13,990 | $116,675 | $110,932 |
| Beginning Cash Position | 85,510 | 85,510 | 85,510 | 93,447 | 93,447 |
| End Cash Position | 48,107 | 62,624 | 52,747 | 85,510 | 61,531 |
| Net Cash Flow | $-37,403 | $-22,886 | $-32,763 | $-7,937 | $-31,916 |
| Free Cash Flow | |||||
| Operating Cash Flow | -121,647 | -91,959 | -52,929 | -200,300 | -163,602 |
| Capital Expenditure | -386 | -143 | -99 | -694 | -437 |
| Free Cash Flow | -122,033 | -92,102 | -53,028 | -200,994 | -164,039 |